Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer

Christina Annette Bjerre; Ann Knoop; Karsten Bjerre; Mathilde S. Larsen; Katrine L. Henriksen; Maria Bibi Lyng; Henrik Ditzel; Birgitte B Rasmussen; Nils Brünner; Bent Ejlertsen; Anne-Vibeke Lænkholm

doi:10.3109/0284186x.2012.734922

Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer

Christina Annette Bjerre, Ann Knoop, Karsten Bjerre, Mathilde S. Larsen, Katrine L. Henriksen, Maria Bibi Lyng, Henrik Ditzel, Birgitte B Rasmussen, Nils Brünner, Bent Ejlertsen, Anne-Vibeke Lænkholm

12 Citations (Scopus)

Abstract

Background. The role of tissue inhibitor of metalloproteinases-1 (TIMP-1) in estrogen receptor (ER) positive breast cancer remains to be fully elucidated. We evaluated TIMP-1 as a prognostic marker in patients treated with adjuvant tamoxifen and investigated TIMP-1s association with Ki67 and ER/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2) profiles. Material and methods. TIMP-1 expression was evaluated by immunohistochemistry (IHC) on formalin fixed paraffin embedded primary tumor tissue in two independent cohorts comprised of 236 and 192 patients, respectively. Results. No differences in disease free survival (HR 0.98; 95% CI 0.63-1.53; p = 0.92) and overall survival (HR 0.94; 95% CI 0.63-1.43; p = 0.79) were observed according to TIMP-1 status. A significant negative association between TIMP-1 and Ki67 was identified (p = 0.015). TIMP-1 expression did not differ significantly according to ER/PR/HER2 profiles. When analyzed as separate variables PR and HER2 status tended to have a positive but non-significant association with TIMP-1 (PR: p = 0.08; OR 2.54; 95% CI 0.91-7.10, HER2: p = 0.08; OR 0.48; 95% CI 0.21-1.08) whereas ER status was not associated with TIMP-1 expression (p = 0.48; OR 0.68; 95% CI 0.23-1.99). Conclusion. TIMP-1 does not appear to be prognostic in breast cancer patients receiving adjuvant tamoxifen. We identified a negative association between TIMP-1 and Ki67. We did not confirm our previous in vitro findings of a negative association between TIMP-1 and PR.

Original language	English
Journal	Acta Oncologica
Volume	52
Issue number	1
Pages (from-to)	82-90
Number of pages	9
ISSN	0284-186X
DOIs	https://doi.org/10.3109/0284186x.2012.734922
Publication status	Published - Jan 2013

Keywords

Aged
Antineoplastic Agents, Hormonal
Breast Neoplasms
Cohort Studies
Female
Humans
Immunohistochemistry
In Situ Hybridization, Fluorescence
Kaplan-Meier Estimate
Ki-67 Antigen
Middle Aged
Multivariate Analysis
Prognosis
Receptor, erbB-2
Receptors, Estrogen
Receptors, Progesterone
Tamoxifen
Tissue Inhibitor of Metalloproteinase-1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/0284186x.2012.734922

Cite this

@article{01f666f2be4541f4a0f2e315e3344f94,

title = "Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer",

abstract = "Background. The role of tissue inhibitor of metalloproteinases-1 (TIMP-1) in estrogen receptor (ER) positive breast cancer remains to be fully elucidated. We evaluated TIMP-1 as a prognostic marker in patients treated with adjuvant tamoxifen and investigated TIMP-1s association with Ki67 and ER/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2) profiles. Material and methods. TIMP-1 expression was evaluated by immunohistochemistry (IHC) on formalin fixed paraffin embedded primary tumor tissue in two independent cohorts comprised of 236 and 192 patients, respectively. Results. No differences in disease free survival (HR 0.98; 95% CI 0.63-1.53; p = 0.92) and overall survival (HR 0.94; 95% CI 0.63-1.43; p = 0.79) were observed according to TIMP-1 status. A significant negative association between TIMP-1 and Ki67 was identified (p = 0.015). TIMP-1 expression did not differ significantly according to ER/PR/HER2 profiles. When analyzed as separate variables PR and HER2 status tended to have a positive but non-significant association with TIMP-1 (PR: p = 0.08; OR 2.54; 95% CI 0.91-7.10, HER2: p = 0.08; OR 0.48; 95% CI 0.21-1.08) whereas ER status was not associated with TIMP-1 expression (p = 0.48; OR 0.68; 95% CI 0.23-1.99). Conclusion. TIMP-1 does not appear to be prognostic in breast cancer patients receiving adjuvant tamoxifen. We identified a negative association between TIMP-1 and Ki67. We did not confirm our previous in vitro findings of a negative association between TIMP-1 and PR.",

keywords = "Aged, Antineoplastic Agents, Hormonal, Breast Neoplasms, Cohort Studies, Female, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Kaplan-Meier Estimate, Ki-67 Antigen, Middle Aged, Multivariate Analysis, Prognosis, Receptor, erbB-2, Receptors, Estrogen, Receptors, Progesterone, Tamoxifen, Tissue Inhibitor of Metalloproteinase-1",

author = "Bjerre, {Christina Annette} and Ann Knoop and Karsten Bjerre and Larsen, {Mathilde S.} and Henriksen, {Katrine L.} and Lyng, {Maria Bibi} and Henrik Ditzel and Rasmussen, {Birgitte B} and Nils Br{\"u}nner and Bent Ejlertsen and Anne-Vibeke L{\ae}nkholm",

year = "2013",

month = jan,

doi = "10.3109/0284186x.2012.734922",

language = "English",

volume = "52",

pages = "82--90",

journal = "Acta Oncologica, Supplement",

issn = "1100-1704",

publisher = "Taylor & Francis",

number = "1",

}

TY - JOUR

T1 - Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer

AU - Bjerre, Christina Annette

AU - Knoop, Ann

AU - Bjerre, Karsten

AU - Larsen, Mathilde S.

AU - Henriksen, Katrine L.

AU - Lyng, Maria Bibi

AU - Ditzel, Henrik

AU - Rasmussen, Birgitte B

AU - Brünner, Nils

AU - Ejlertsen, Bent

AU - Lænkholm, Anne-Vibeke

PY - 2013/1

Y1 - 2013/1

N2 - Background. The role of tissue inhibitor of metalloproteinases-1 (TIMP-1) in estrogen receptor (ER) positive breast cancer remains to be fully elucidated. We evaluated TIMP-1 as a prognostic marker in patients treated with adjuvant tamoxifen and investigated TIMP-1s association with Ki67 and ER/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2) profiles. Material and methods. TIMP-1 expression was evaluated by immunohistochemistry (IHC) on formalin fixed paraffin embedded primary tumor tissue in two independent cohorts comprised of 236 and 192 patients, respectively. Results. No differences in disease free survival (HR 0.98; 95% CI 0.63-1.53; p = 0.92) and overall survival (HR 0.94; 95% CI 0.63-1.43; p = 0.79) were observed according to TIMP-1 status. A significant negative association between TIMP-1 and Ki67 was identified (p = 0.015). TIMP-1 expression did not differ significantly according to ER/PR/HER2 profiles. When analyzed as separate variables PR and HER2 status tended to have a positive but non-significant association with TIMP-1 (PR: p = 0.08; OR 2.54; 95% CI 0.91-7.10, HER2: p = 0.08; OR 0.48; 95% CI 0.21-1.08) whereas ER status was not associated with TIMP-1 expression (p = 0.48; OR 0.68; 95% CI 0.23-1.99). Conclusion. TIMP-1 does not appear to be prognostic in breast cancer patients receiving adjuvant tamoxifen. We identified a negative association between TIMP-1 and Ki67. We did not confirm our previous in vitro findings of a negative association between TIMP-1 and PR.

AB - Background. The role of tissue inhibitor of metalloproteinases-1 (TIMP-1) in estrogen receptor (ER) positive breast cancer remains to be fully elucidated. We evaluated TIMP-1 as a prognostic marker in patients treated with adjuvant tamoxifen and investigated TIMP-1s association with Ki67 and ER/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2) profiles. Material and methods. TIMP-1 expression was evaluated by immunohistochemistry (IHC) on formalin fixed paraffin embedded primary tumor tissue in two independent cohorts comprised of 236 and 192 patients, respectively. Results. No differences in disease free survival (HR 0.98; 95% CI 0.63-1.53; p = 0.92) and overall survival (HR 0.94; 95% CI 0.63-1.43; p = 0.79) were observed according to TIMP-1 status. A significant negative association between TIMP-1 and Ki67 was identified (p = 0.015). TIMP-1 expression did not differ significantly according to ER/PR/HER2 profiles. When analyzed as separate variables PR and HER2 status tended to have a positive but non-significant association with TIMP-1 (PR: p = 0.08; OR 2.54; 95% CI 0.91-7.10, HER2: p = 0.08; OR 0.48; 95% CI 0.21-1.08) whereas ER status was not associated with TIMP-1 expression (p = 0.48; OR 0.68; 95% CI 0.23-1.99). Conclusion. TIMP-1 does not appear to be prognostic in breast cancer patients receiving adjuvant tamoxifen. We identified a negative association between TIMP-1 and Ki67. We did not confirm our previous in vitro findings of a negative association between TIMP-1 and PR.

KW - Aged

KW - Antineoplastic Agents, Hormonal

KW - Breast Neoplasms

KW - Cohort Studies

KW - Female

KW - Humans

KW - Immunohistochemistry

KW - In Situ Hybridization, Fluorescence

KW - Kaplan-Meier Estimate

KW - Ki-67 Antigen

KW - Middle Aged

KW - Multivariate Analysis

KW - Prognosis

KW - Receptor, erbB-2

KW - Receptors, Estrogen

KW - Receptors, Progesterone

KW - Tamoxifen

KW - Tissue Inhibitor of Metalloproteinase-1

U2 - 10.3109/0284186x.2012.734922

DO - 10.3109/0284186x.2012.734922

M3 - Journal article

C2 - 23205744

SN - 1100-1704

VL - 52

SP - 82

EP - 90

JO - Acta Oncologica, Supplement

JF - Acta Oncologica, Supplement

IS - 1

ER -

Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this